Targeted Oncology3h
Experience Managing irAEs Vital for Both Oncologists and Specialists
During a live event, James W. Smithy, MD, MHS, and other oncologists discussed how their experience with immune-related ...
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Nanobiotix S.A. Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose ...
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)
Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients ...
Healio4h
VIDEO: Dual immunotherapy outperforms monotherapy in metastatic colorectal cancer
In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.
PharmiWeb13h
PD-1 and PD-L1 Inhibitors Market: Trends, Growth, and Future Prospects
IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...